Tower Research Capital (TRC)’s DataMeds AI MEDS Stock Holding History
Bought
Maintained
Sold
Other funds holding MEDS
PFGI
RMI
Tower Research Capital (TRC)'s MEDS Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its DataMeds AI (MEDS) stake by 909% in Q3 2026, buying an estimated $15.1K and bringing the position to 6,841 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3750.
Tower Research Capital (TRC) first reported a position in MEDS in Q3 2025 and has held it in 4 quarters since. 16 funds tracked by Wall St. Rank hold MEDS as of Q3 2026.
- Tower Research Capital (TRC) held 6,841 shares of DataMeds AI worth $21.7K as of Q3 2026.
- Tower Research Capital (TRC) bought 6,163 DataMeds AI shares in Q3 2026, an estimated $15.1K.
- DataMeds AI made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3750 holding.
- Tower Research Capital (TRC) first reported a position in DataMeds AI in Q3 2025 and has held it in 4 quarters since.
- 16 funds tracked by Wall St. Rank held DataMeds AI as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.